International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries
View Full Paper
Ask AI
Bookmark
Share
Key result
Among patients with new-onset atrial fibrillation, non-vitamin K antagonist oral anticoagulant use increased over time to 43% in GARFIELD-AF and 71% in ORBIT-AF II by 2016, while antiplatelet monotherapy decreased.
Population
73,004 patients with atrial fibrillation from 35 countries, comprising the GARFIELD-AF, ORBIT-AF I, and…
Design
Cohort
Authors
Discussion
Loading...
Member takes
Implication
OAC use varies by risk score and registry; hypothesis-generating for factors driving real-world adherence in AF.
Study Design
Type
Observational (n=73,004)
Multicenter
Yes
Structured PICO
P
Population
73,004 patients with atrial fibrillation from 35 countries enrolled in the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries to assess international patterns of stroke prevention treatment.
E
Exposure
Oral anticoagulation (OAC) treatment, including non-vitamin K antagonist oral anticoagulants (NOACs) and antiplatelet therapy.
O
Outcome
International patterns of atrial fibrillation stroke prevention treatment (oral anticoagulant and antiplatelet use) stratified by stroke risk (CHA2DS2-VASc score) and geography.
Limitations
- Sampling and/or selection biases in observational registry data
- Geographic imbalance in enrollment of patients with potential overrepresentation of some regions
- Differences in design and enrollment criteria between the registries
- Data acquired via medical record review with different verification and auditing protocols
- Geographic imbalance in enrollment
- Differences in design and enrollment criteria between registries
- Data acquired via medical record review with different verification protocols
Cite This Study
Steinberg et al. (2017) conducted an observational in Atrial fibrillation (n=73,004). Non-vitamin K antagonist oral anticoagulants (NOACs) vs. Antiplatelet monotherapy or no therapy was evaluated on Use of non-vitamin K antagonist oral anticoagulants (NOACs) and antiplatelet monotherapy over time. Among patients with new-onset atrial fibrillation, non-vitamin K antagonist oral anticoagulant use increased over time to 43% in GARFIELD-AF and 71% in ORBIT-AF II by 2016, while antiplatelet monotherapy decreased.
Topics
View Full Paper
Ask AI
Bookmark
Share